DTC
MAZE

Deep Track Capital’s Maze Therapeutics MAZE Stock Holding History

Deep Track Capital’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104M Sell
3,477,562
-768,878
-18% -$33.9M 1.7% 17
2025
Q4 		$176M Buy
4,246,440
+297,530
+8% +$10.2M 3.14% 11
2025
Q3 		$102M Hold
3,948,910
– – 2.86% 16
2025
Q2 		$48.5M Buy
3,948,910
+679,784
+21% +$7.07M 1.55% 21
2025
Q1 		$36M Buy
+3,269,126
New +$39.4M 1.17% 24

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Deep Track Capital's MAZE Position: Q1 2026 in Review

Deep Track Capital reduced its Maze Therapeutics (MAZE) stake by 18% in Q1 2026, selling an estimated $33.9M and leaving 3,477,562 shares worth $104M. The position accounts for 1.7% of the portfolio, ranked #17.

Deep Track Capital first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $176M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Deep Track Capital held 3,477,562 shares of Maze Therapeutics worth $104M as of Q1 2026.
  • Deep Track Capital sold 768,878 Maze Therapeutics shares in Q1 2026, an estimated $33.9M.
  • Maze Therapeutics made up 1.7% of Deep Track Capital's portfolio in Q1 2026, its #17 holding.
  • Deep Track Capital first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Deep Track Capital's Maze Therapeutics position peaked at $176M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.